Atossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Atossa Therapeutics, Inc. (NASDAQ:ATOSGet Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.42 and traded as high as $1.44. Atossa Therapeutics shares last traded at $1.44, with a volume of 357,218 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ATOS shares. Ascendiant Capital Markets increased their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Atossa Therapeutics in a research note on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th.

Read Our Latest Research Report on Atossa Therapeutics

Atossa Therapeutics Price Performance

The stock has a 50 day simple moving average of $1.37 and a two-hundred day simple moving average of $1.42. The company has a market capitalization of $181.09 million, a price-to-earnings ratio of -6.86 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts predict that Atossa Therapeutics, Inc. will post -0.22 EPS for the current year.

Institutional Trading of Atossa Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATOS. Vanguard Group Inc. grew its holdings in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after buying an additional 164,540 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Atossa Therapeutics during the second quarter worth about $161,000. Finally, Virtu Financial LLC purchased a new position in shares of Atossa Therapeutics during the first quarter worth about $151,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Stories

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.